



Kilitch Drugs (India) Ltd.

04-03-2022

To
Department of Corporate Services,
BSE-Limited
PJ Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No C-1, G Block,
BKC, Bandra (E)- Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Dear Sir/ Madam,

Sub: Kilitch Drugs (India) Limited - Press Release

Please find enclosed Press Release titled “Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan.”

The above is for information and dissemination to the public at large.

Thanking you

Yours faithfully

For Kilitch Drugs (India) Limited

Mukund Mehta
Managing Director
DIN: 00147876





Kilitch Drugs (India) Ltd.

Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan

Mumbai March 04, 2022, Kilitch Drugs India Limited is a Leading MSME multinational manufacturer of Injectables in India and Ethiopia. Kilitch has purchased 15 Acres land parcel in Village: Maldev, Taluka: Pen, on Pen – Khopoli Highway, Maharashtra as beginning of its expansion plan.

The land bought by the company will be used for establishing a state-of-the-art greenfield pharma complex. The company plans to set up 4-6 manufacturing units in different therapeutics categories to cater to the growing demands in Domestic and Exports markets. The expansion will be in a similar line of Injectables and other Biotech products. The project envisaged is futuristic and shall have maximum recognition of the world's leading regulatory authorities.

Commenting on this **Mr. Mukund Mehta, Chairman & Managing Director of Kilitch Drugs said** "We are on a growth trajectory and demand for our products is increasing. This expansion will help us to fuel our growth plan. This will be an ultra-modern facility and the capex requirement for this facility will be in tune of approx. Rs. 100 Crore.

We are planning to fund the capex mostly through internal accruals and it will be in a phased manner. We are looking for a horizon of 2 years to commence commercial production of Phase I. Once the total expansion is complete it will generate Revenue opportunity of approx. Rs. 500 Crore "

About Kilitch Drugs (India) Limited:

Established in 1978, Kilitch Drug (India) is a successful pharmaceutical solution company. Company has major focus in African region and have strong foothold across key African countries with 350 products in 26 African countries.

The Company has manufacturing plant located in Mumbai with a dedicated dry powder section and small volume liquid ampoules and vial. In 2018 the Company has started greenfield project in Ethiopia for Cephalosporins Injectables. The Company's manufacturing plants are certified by WHO, WHO GMP, ISO 9001, ISO 13845 etc.

The Company's strong clientele includes Intas, Mankind, Indoco Remedies to name among few.

For FY21 the Company has achieved Total Revenue of Rs. 74.21 crore with PAT of Rs. 6.16 crore

For Further Information:

Ms. Princy Asati
Company Secretary
Kilitch Drugs (India) Limited

Date- 04-03-2022
Mumbai